RNA - Avidity Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
RNA price evolution
RNA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $578.55 | $471.69 | $185.38 | |
| Short term investments | $723.29 | $444.47 | $410.27 | |
| Net receivables | $1.57 | $1.1 | ||
| Inventory | ||||
| Total current assets | $1621.87 | $1328.8 | $934.47 | $611.31 |
| Long term investments | ||||
| Property, plant & equipment | $15.79 | $15.46 | $16.28 | $16.65 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $18.62 | $17 | $17.25 | |
| Total investments | $723.29 | $444.47 | $410.27 | |
| Total assets | $1640.77 | $1347.42 | $951.47 | $628.55 |
| Current liabilities | ||||
| Accounts payable | $7.66 | $40.92 | $37.33 | $34.34 |
| Deferred revenue | $64.26 | $66.3 | $69.26 | |
| Short long term debt | $3.77 | $3.73 | $3.64 | |
| Total current liabilities | $91.33 | $84.21 | $74.95 | $80.68 |
| Long term debt | $4.62 | $5.42 | $6.21 | |
| Total noncurrent liabilities | $42.18 | $45.62 | $47.11 | |
| Total debt | $8.38 | $9.15 | $9.85 | |
| Total liabilities | $137.39 | $126.39 | $120.58 | $127.79 |
| Shareholders' equity | ||||
| Retained earnings | -$790.81 | -$710.41 | -$639.62 | -$570.76 |
| Other shareholder equity | $7.1 | -$0.45 | -$0.46 | $0.13 |
| Total shareholder equity | $1221.04 | $830.9 | $500.76 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $185.38 | $340.65 | $320.7 | $321.71 |
| Short term investments | $410.27 | $270.33 | $85.09 | $6.68 |
| Net receivables | $1.1 | |||
| Inventory | ||||
| Total current assets | $611.31 | $622.94 | $411.14 | $331.68 |
| Long term investments | ||||
| Property, plant & equipment | $16.65 | $15.01 | $15.59 | $1.47 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $17.25 | $15.86 | $16.44 | $2.22 |
| Total investments | $410.27 | $270.33 | $85.09 | $6.68 |
| Total assets | $628.55 | $638.8 | $427.58 | $333.9 |
| Current liabilities | ||||
| Accounts payable | $34.34 | $32.57 | $14.09 | $7.75 |
| Deferred revenue | $69.26 | $6.28 | $11.4 | $15.84 |
| Short long term debt | $3.64 | $3.1 | $1.77 | |
| Total current liabilities | $80.68 | $51.91 | $29.66 | $14.59 |
| Long term debt | $6.21 | $7.58 | $9.96 | $0.94 |
| Total noncurrent liabilities | $47.11 | $8.82 | $16.49 | $13.09 |
| Total debt | $9.85 | $10.69 | $11.73 | $0.94 |
| Total liabilities | $127.79 | $60.73 | $46.15 | $27.68 |
| Shareholders' equity | ||||
| Retained earnings | -$570.76 | -$358.54 | -$184.55 | -$66.54 |
| Other shareholder equity | $0.13 | -$2.7 | -$0.19 | -$0.01 |
| Total shareholder equity | $500.76 | $578.08 | $381.43 | $306.22 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.34 | $2.04 | $3.54 | $2.19 |
| Cost of revenue | ||||
| Gross Profit | $2.04 | $3.54 | $2.19 | |
| Operating activities | ||||
| Research & development | $63.94 | $66.83 | $52.82 | |
| Selling, general & administrative | $20.73 | $13.9 | $16.12 | |
| Total operating expenses | $100.47 | $84.67 | $80.73 | $68.94 |
| Operating income | -$82.63 | -$77.19 | -$66.74 | |
| Income from continuing operations | ||||
| EBIT | -$70.79 | -$68.86 | -$60.44 | |
| Income tax expense | ||||
| Interest expense | $17.97 | |||
| Net income | ||||
| Net income | -$80.4 | -$70.79 | -$68.86 | -$60.44 |
| Income (for common shares) | -$70.79 | -$68.86 | -$60.44 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.56 | $9.22 | $9.33 | $6.79 |
| Cost of revenue | ||||
| Gross Profit | $9.56 | $9.22 | $9.33 | $6.79 |
| Operating activities | ||||
| Research & development | $190.97 | $150.4 | $101.18 | $37.6 |
| Selling, general & administrative | $54.19 | $37.73 | $26.2 | $13.46 |
| Total operating expenses | $245.16 | $188.14 | $127.38 | $51.06 |
| Operating income | -$235.6 | -$178.91 | -$118.05 | -$44.28 |
| Income from continuing operations | ||||
| EBIT | -$212.22 | -$174 | -$118.01 | -$44.15 |
| Income tax expense | ||||
| Interest expense | $0.21 | |||
| Net income | ||||
| Net income | -$212.22 | -$174 | -$118.01 | -$44.35 |
| Income (for common shares) | -$212.22 | -$174 | -$118.01 | -$44.35 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$70.79 | -$68.86 | -$60.44 | |
| Operating activities | ||||
| Depreciation | $1.51 | $1.47 | $1.44 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $12.81 | $10.31 | $9.85 | |
| Total cash flows from operations | -$65 | -$70.38 | $16.5 | |
| Investing activities | ||||
| Capital expenditures | -$0.53 | -$0.92 | -$0.86 | |
| Investments | -$274.34 | -$31.83 | $51.9 | |
| Total cash flows from investing | -$790.03 | -$274.87 | -$32.75 | $51.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $446.72 | $389.44 | $31.89 | |
| Net borrowings | ||||
| Total cash flows from financing | $1178.63 | $446.72 | $389.44 | $31.89 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $187.61 | $106.85 | $286.32 | $99.43 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$212.22 | -$174 | -$118.01 | -$44.35 |
| Operating activities | ||||
| Depreciation | $5.08 | $1.39 | $0.64 | $0.37 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $38.22 | $27.14 | $17.06 | $4.31 |
| Total cash flows from operations | -$119.06 | -$136.27 | -$94.81 | -$37.12 |
| Investing activities | ||||
| Capital expenditures | -$4.23 | -$2.82 | -$3.74 | -$1.09 |
| Investments | -$125.84 | -$187.13 | -$78.78 | -$6.69 |
| Total cash flows from investing | -$130.07 | -$189.96 | -$82.52 | -$7.79 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $93.86 | $346.17 | $176.32 | $274.52 |
| Net borrowings | -$4.68 | |||
| Total cash flows from financing | $93.86 | $346.17 | $176.32 | $272.04 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$155.27 | $19.95 | -$1.01 | $227.13 |
News
Fundamentals
| Market cap | $8.60B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 118.90M |
| Revenue | $10.12M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$280.49M |
| Revenue Q/Q | -17.10% |
| Revenue Y/Y | -0.19% |
| P/E ratio | -30.67 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 850.18 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.36 |
|---|---|
| ROA | -24.56% |
| ROE | N/A |
| Debt/Equity | 0.26 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 17.76 |
| Quick ratio | N/A |